Exploration of HIV Reservoirs

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

11 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-05-31

Study Completion Date

2009-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective study in HIV-1 infected patients with a plasma viral load below the limit of detection and stable for at least 5 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comprehensive Analysis of HIV Reservoirs in Chronically Infected HIV-1 Treated Patients

NCT02628340

HIV

COMPLETED

Role of Viral Reservoir, Immune Activation and Depletion in Persistent Viremia Persistent Viremia in People Living With HIV on Antiretroviral Therapy

NCT07015164

HIV

NOT_YET_RECRUITING

Assessing the Severity of Metabolic-related Liver Injuries in Aging HIV-monoinfected Patients

NCT02093754

HIV Infection Liver Injuries

COMPLETED NA

HIV Study on MEasuring the Reservoir on Cellular Level to CUre Infection

NCT04305665

Hiv

RECRUITING

Tissue Biopsy and Imaging Studies in HIV-Infected Patients

NCT00001471

HIV ICL Healthy Volunteers

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Evaluation of the mucosal HIV reservoirs (HIV-DNA quantification and distribution of the infected T lymphocytes in the gut mucosa associated lymphoid tissue compared to the blood in HIV-1 infected patients under antiretroviral treatment with an undetectable plasma viral load below the 50 copies/ml limit of detection for at least 5 years).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV-1 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rectal mucosa biopsy

Rectal mucosa samples collection

Rectal mucosa biopsy

Intervention Type PROCEDURE

Collection of a maximum of 15 rectal mucosa samples in the high portion of the rectum near the rectosigmoidal junction

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rectal mucosa biopsy

Collection of a maximum of 15 rectal mucosa samples in the high portion of the rectum near the rectosigmoidal junction

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV-1 documented infection
* HIV-1 plasma viral load measurable before antiretroviral treatment initiation
* Patients treated with an antiretroviral combination containing a protease inhibitor and/or a non-nucleosidic reverse transcriptase inhibitor without any interruption since treatment initiation
* Patients with a stable plasma viral load below the limit of detection (HIV-RNA \< 50 copies/ml since January 2006 and/or HIV-RNA \< 200 copies/ml during the anterior period) under antiretroviral treatment for at least 5 years and for at least 90 % of the measures

Exclusion Criteria

* Contraindication to the biopsy
* No ability or willingness to provide informed consent
* Concomitant treatment with antithrombotics or platelets antiaggregatory
* Patients co-infected with HCV and or HBV
* Patients who received an immunosuppressive treatment during 3 months prior enrollment (chemotherapy, radiotherapy, corticotherapy, splenectomy) or an immunotherapy during 5 years prior enrolment (IL-2, anti-HIV vaccine, IFN-alpha)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No